Advertisement

International Urology and Nephrology

, Volume 52, Issue 1, pp 1–8 | Cite as

HPV infection in urology practice

  • Mehmet SarierEmail author
  • Ali Murat Ceyhan
  • Nevgun Sepin
  • Esin Ozel
  • Mehmet Murat Inal
  • Erdal Kukul
  • Ahmet Soylu
Urology - Review

Abstract

Human papillomavirus (HPV) is the most common pathogen of sexually transmitted disease worldwide. While HPV is responsible for low-grade benign lesions in the anogenital area such as condyloma acuminatum, it is also strongly associated with cervical, anal, vulvar/vaginal, and penile carcinomas. In addition to being an oncogenic virus, HPV causes a substantial socioeconomic burden due to the recurrence of benign lesions, the lack of a definitive treatment option that provides a complete cure, and the high cost of treatment. The global incidence of HPV infection is rising, especially among young and sexually active individuals; as a result, in recent years these infections have also become increasingly conspicuous in urology practice, both as incidental findings and primary complaints. The aim of this review is to evaluate the pathogenesis, diagnosis, and treatment modalities of HPV infections in light of the current literature from the urologist’s perspective.

Keywords

HPV Human papillomavirus Condyloma acuminatum Wart Urology 

Abbreviations

CA

Condyloma acuminatum

CDC

Centers for disease control and prevention

DNA

Deoxyribonucleic acid

FDA

Food and drug administration

HPV

Human papilomavirus

PCR

Polymerase chain reaction

RB

Retinoblastoma

Notes

Funding

No funding received for this work.

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

References

  1. 1.
    Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S (2014) Human papillomaviruses in urological malignancies: a critical assessment. Urol Oncol 32(1):46.e19–46.e27.  https://doi.org/10.1016/j.urolonc.2013.06.012 CrossRefGoogle Scholar
  2. 2.
    Cobos C, Figueroa JA, Mirandola L et al (2014) The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol 33(5):383–401.  https://doi.org/10.3109/08830185.2014.911857 CrossRefPubMedGoogle Scholar
  3. 3.
    Heidegger I, Borena W, Pichler R (2015) The role of human papilloma virus in urological malignancies. Anticancer Res 35(5):2513–2519. http://www.ncbi.nlm.nih.gov/pubmed/25964524. Accessed 30 Nov 2018
  4. 4.
    Sarier M, Sepin N, Keles Y et al (2019) Is there any association between urothelial carcinoma of the bladder and human papillomavirus? A case-control study. Urol Int 2019:1–6.  https://doi.org/10.1159/000500467 CrossRefGoogle Scholar
  5. 5.
    Stanley M (2006) Immune responses to human papillomavirus. Vaccine 24:S16–S22.  https://doi.org/10.1016/j.vaccine.2005.09.002 CrossRefPubMedGoogle Scholar
  6. 6.
    Avcı GA, Gülendam B (2013) Human papillomavirus. Kafkas J Med Sci 3(3):136–144.  https://doi.org/10.5505/kmjs.2013.52724 CrossRefGoogle Scholar
  7. 7.
    Garolla A, Pizzol D, Bertoldo A, De Toni L, Barzon L, Foresta C (2013) Association, prevalence, and clearance of human papillomavirus and antisperm antibodies in infected semen samples from infertile patients. Fertil Steril 99(1):125–131.  https://doi.org/10.1016/J.FERTNSTERT.2012.09.006 CrossRefPubMedGoogle Scholar
  8. 8.
    Liu M, He Z, Zhang C et al (2014) Prevalence, incidence, clearance, and associated factors of genital human papillomavirus infection among men: a population-based cohort study in rural China. Cancer Epidemiol Biomarkers Prev 23(12):2857–2865.  https://doi.org/10.1158/1055-9965.EPI-14-0365 CrossRefPubMedGoogle Scholar
  9. 9.
    Muñoz N, Méndez F, Posso H et al (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of colombian women with normal cytological results. J Infect Dis 190(12):2077–2087.  https://doi.org/10.1086/425907 CrossRefPubMedGoogle Scholar
  10. 10.
    Muñoz N, Bosch FX, de Sanjosé S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527.  https://doi.org/10.1056/NEJMoa021641 CrossRefPubMedGoogle Scholar
  11. 11.
    Ma X, Wang Q, Ong JJ et al (2018) Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis. Sex Transm Infect 94(6):434–442.  https://doi.org/10.1136/sextrans-2017-053412 CrossRefPubMedGoogle Scholar
  12. 12.
    Stanley MA, Pett MR, Coleman N (2007) HPV: from infection to cancer. Biochem Soc Trans 35(6):1456–1460.  https://doi.org/10.1042/BST0351456 CrossRefPubMedGoogle Scholar
  13. 13.
    Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR (2010) Consistent condom use is associated with lower prevalence of human papillomavirus infection in men. J Infect Dis 202(3):445–451.  https://doi.org/10.1086/653708 CrossRefPubMedGoogle Scholar
  14. 14.
    Schneider A (1993) Pathogenesis of genital HPV infection. Genitourin Med 69(3):165–173. http://www.ncbi.nlm.nih.gov/pubmed/8392965. Accessed 15 Apr 2019CrossRefGoogle Scholar
  15. 15.
    Münger K (2002) The role of human papillomaviruses in human cancers. Front Biosci 7:d641–9. http://www.ncbi.nlm.nih.gov/pubmed/11861215. Accessed 15 Apr 2019CrossRefGoogle Scholar
  16. 16.
    Andersen ES, Thorup K, Larsen G (1988) The results of cryosurgery for cervical intraepithelial neoplasia. Gynecol Oncol 30(1):21–25. http://www.ncbi.nlm.nih.gov/pubmed/3366393. Accessed 15 Apr 2019CrossRefGoogle Scholar
  17. 17.
    Mayrand M-H, Duarte-Franco E, Rodrigues I et al (2007) Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med 357(16):1579–1588.  https://doi.org/10.1056/NEJMoa071430 CrossRefPubMedGoogle Scholar
  18. 18.
    Kösel S, Burggraf S, Mommsen J, Engelhardt W, Olgemöller B (2003) Type-specific detection of human papillomaviruses in a routine laboratory setting–improved sensitivity and specificity of PCR and sequence analysis compared to direct hybridisation. Clin Chem Lab Med 41(6):787–791.  https://doi.org/10.1515/CCLM.2003.119 CrossRefPubMedGoogle Scholar
  19. 19.
    Cai T, Mazzoli S, Meacci F et al (2011) Human papillomavirus and non-muscle invasive urothelial bladder cancer: potential relationship from a pilot study. Oncol Rep 25(2):485–489.  https://doi.org/10.3892/or.2010.1083 CrossRefPubMedGoogle Scholar
  20. 20.
    Nilyanimit P, Chansaenroj J, Srisomboon J et al (2018) Human papillomavirus in thai women and men with anogenital warts. Intervirology 61(5):223–229.  https://doi.org/10.1159/000497351 CrossRefPubMedGoogle Scholar
  21. 21.
    Gall SA (2001) Female genital warts: global trends and treatments. Infect Dis Obstet Gynecol 9(3):149–154.  https://doi.org/10.1155/S1064744901000278 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kilciler M, Bedir S, Erdemir F et al (2007) Condylomata acuminata of external urethral meatus causing infravesical obstruction. Int Urol Nephrol 39(1):107–109.  https://doi.org/10.1007/s11255-005-4986-3 CrossRefPubMedGoogle Scholar
  23. 23.
    Camenga DR, Dunne EF, Desai MM et al (2013) Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis 40(7):534–538.  https://doi.org/10.1097/OLQ.0b013e3182953ce0 CrossRefPubMedGoogle Scholar
  24. 24.
    Sarier M, Ozel E, Duman I, Yuksel Y, Demirbas A (2017) HPV type 45-positive condyloma acuminata of the bladder in a renal transplant recipient. Transpl Infect Dis 19(2):e12667.  https://doi.org/10.1111/tid.12667 CrossRefGoogle Scholar
  25. 25.
    Giuliano AR, Lee JH, Fulp W et al (2011) Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet.  https://doi.org/10.1016/S0140-6736(10)62342-2 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Assmann G, Sotlar K (2011) HPV-associated squamous cell carcinogenesis. Pathologe 32(5):391–398.  https://doi.org/10.1007/s00292-011-1442-2 CrossRefPubMedGoogle Scholar
  27. 27.
    Giuliano AR, Tortolero-Luna G, Ferrer E et al (2008) Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 26:K17–K28.  https://doi.org/10.1016/j.vaccine.2008.06.021 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Marchionne E, Perez C, Hui A, Khachemoune A (2017) Penile squamous cell carcinoma: a review of the literature and case report treated with Mohs micrographic surgery. An Bras Dermatol 92(1):95–99.  https://doi.org/10.1590/abd1806-4841.20175009 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kraus I, Molden T, Holm R et al (2006) Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 44(4):1310–1317.  https://doi.org/10.1128/JCM.44.4.1310-1317.2006 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Longworth MS, Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68(2):362–372.  https://doi.org/10.1128/MMBR.68.2.362-372.2004 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Shaker OG, Hammam OA, Wishahi MM (2013) Is there a correlation between HPV and urinary bladder carcinoma? Biomed Pharmacother 67(3):183–191.  https://doi.org/10.1016/j.biopha.2012.10.019 CrossRefPubMedGoogle Scholar
  32. 32.
    Gould VE, Schmitt M, Vinokurova S et al (2010) Human papillomavirus and p16 expression in inverted papillomas of the urinary bladder. Cancer Lett 292(2):171–175.  https://doi.org/10.1016/j.canlet.2009.11.022 CrossRefPubMedGoogle Scholar
  33. 33.
    Gutiérrez J, Jiménez A, de Dios Luna J, Soto MJ, Sorlózano A (2006) Meta-analysis of studies analyzing the relationship between bladder cancer and infection by human papillomavirus. J Urol 176((6 Pt 1)):2474–2481.  https://doi.org/10.1016/j.juro.2006.07.157(discussion 2481) CrossRefPubMedGoogle Scholar
  34. 34.
    Mai S, Welzel G, Ottstadt M et al (2015) Prognostic relevance of HPV infection and p16 overexpression in squamous cell anal cancer. Int J Radiat Oncol Biol Phys 93(4):819–827.  https://doi.org/10.1016/j.ijrobp.2015.08.004 CrossRefPubMedGoogle Scholar
  35. 35.
    Lopaschuk CC (2013) New approach to managing genital warts. Can Fam Physician 59(7):731-736. http://www.ncbi.nlm.nih.gov/pubmed/23851535. Accessed 7 May 2019
  36. 36.
    Ockenfels HM (2016) Therapeutic management of cutaneous and genital warts. JDDG 14(9):892–899.  https://doi.org/10.1111/ddg.12838 CrossRefPubMedGoogle Scholar
  37. 37.
    de Camargo CC, D’Elia MPB, Miot HA (2017) Quality of life in men diagnosed with anogenital warts. An Bras Dermatol 92(3):427–429.  https://doi.org/10.1590/abd1806-4841.20175282 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Mistrangelo M, Dal Conte I, Volpatto S et al (2018) Current treatments for anal condylomata acuminata. Minerva Chir 73(1):100–106.  https://doi.org/10.23736/S0026-4733.17.07554-X CrossRefPubMedGoogle Scholar
  39. 39.
    Scheinfeld N (2013) Update on the treatment of genital warts. Dermatol Online J 20;19(6):18559. http://www.ncbi.nlm.nih.gov/pubmed/24011309. Accessed 7 May 2019
  40. 40.
    Yanofsky VR, Patel R V, Goldenberg G (2012) Genital warts: a comprehensive review. J Clin Aesthet Dermatol 5(6):25–36. http://www.ncbi.nlm.nih.gov/pubmed/22768354. Accessed 7 May 2019
  41. 41.
    Yuan J, Ni G, Wang T et al (2018) Genital warts treatment: beyond imiquimod. Hum Vaccin Immunother 14(7):1815–1819.  https://doi.org/10.1080/21645515.2018.1445947 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Steben M, Garland SM (2014) Genital warts. Best Pract Res Clin Obstet Gynaecol 28(7):1063–1073.  https://doi.org/10.1016/j.bpobgyn.2014.07.002 CrossRefPubMedGoogle Scholar
  43. 43.
    Yılmaz Ö, Okçelik S, Yeşildal C, Soydan H, Ateş FŞT (2017) Our surgical treatment results in urethral condylomata acuminata cases. New J Urol 12(1):36–39Google Scholar
  44. 44.
    Hancock G, Hellner K, Dorrell L (2018) Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol 47:59–72.  https://doi.org/10.1016/j.bpobgyn.2017.09.008 CrossRefPubMedGoogle Scholar
  45. 45.
    Gallagher KE, LaMontagne DS, Watson-Jones D (2018) Status of HPV vaccine introduction and barriers to country uptake. Vaccine 36((32 Pt A)):4761–4767  https://doi.org/10.1016/j.vaccine.2018.02.003 CrossRefPubMedGoogle Scholar
  46. 46.
    Meites E, Kempe A, Markowitz LE (2016) Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the advisory committee on immunization practices. MMWR 65(49):1405–1408.  https://doi.org/10.15585/mmwr.mm6549a5 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of UrologyIstinye UniversityIstanbulTurkey
  2. 2.Department of DermatologyMedical Park HospitalAntalyaTurkey
  3. 3.Department of Clinical Microbiology and Infectious DiseaseEducation and Research HospitalAntalyaTurkey
  4. 4.Department of PathologyAntalya Pathology LaboratoriesAntalyaTurkey
  5. 5.Department of Obstetrics and GynaecologyMemorial HospitalAntalyaTurkey
  6. 6.Department of UrologyMedical Park HospitalAntalyaTurkey
  7. 7.Department of UrologyGozde Academy HospitalMalatyaTurkey

Personalised recommendations